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INTRODUCTION 
 Nutrition has an important role in prevention and management of cancer. It 
also prolongs the life. It gives the essential elements needed for the cell survival. 
Providing better nutrition to cancer patient while on treatment helps to reduce the 
treatment related adverse effects and treatment delays. 
 Malignancy had an impact on food intake symptoms like; dry mouth, 
alteration in taste and smell of food, pain, dyspnoea and fatigue also affect food 
intake. Lung cancer is usually managed by chemotherapy and radiotherapy rarely 
by surgical resection. These treatments also affect food intake. These leads further 
deterioration of patient’s nutritional condition. 
 Patients’ performance status determines the treatment plan1. Reduced food 
intake affects the performance status and management options. 
 Prevalence of malnutrition in stage III/IV Lung cancer is 45-60%2. They 
experience a certain degree of anorexia and early satisfy before starting the 
treatment. These effects results in reduced food intake and more weight loss. 
 Under-nutrition leads to poor outcome in lung cancer patients. Malnourished 
patient had poor tolerance to treatment. Interventions that helps in improving 
nutritional status of patients with lung cancer results in better tolerability treatment 
and have prolonged life3. 
 There is much evidence is available to state that good nutritional support 
results in better treatment outcome. But its use in clinical practices is limited. This 
is due to lack of awareness among the health care professional and added cost of 
treatment. 
The goal of nutritional therapy is to provide patient specific dietary 
counseling and to provide adequate food supplements by orally or parentraly. This 
approach is to be started at earlier phase of treatment that helps in improving the 
nutritional condition and performance status of the patient, which leads to better 
treatment tolerability and prolonged life. 
EPIDEMIOLOGY OF LUNG CANCER 
 Cancer is one of the major non- communicable disease burden in India and 
world wide. In India, the projected number of cancer cases for the year 2020 are 
11, 48,757, among them tobacco related cancers contribute 2, 25,251 cases. 
Estimated number of lung cancer, among men is 47,622 in the year 2015 and 
51,193 in the year 2020. In female ICMR expects 14,705 cases in the year 2015 
and 16,025 cases in the year 20204. 
 The prevalence of under nutrition in cancer patients is 30-85%. It is more in 
gastrointestinal, long and prostate cancer patients. In lung cancer patients 
prevalence of under nutrition ranges from 45-60%2. (Table 1) 
 
PATHOPHYSIOLOGY OF MALNUTRITION IN LUNG CANCER 
 Lung cancer patients suffer from many symptoms like, breathlessness, 
cough, fatigue and pain. Chemotherapy and radiotherapy treatment can also cause, 
nausea, vomiting, mucositis, taste and smell alteration. These symptoms lead to 
poor intake of food, which leads to weight loss, malnutrition, poor response or 
tolerance to cancer treatment and impaired quality of life5.(Figure 1) 
 Tumor and host cells compete with each other for nutrients which results in 
altered metabolism that leads to a state of accelerated starvation. This evolves into 
increased resting energy expenditure (REE) and energy insufficiency6. 
 Cancer affects the metabolism of protein, fat and carbohydrate. This leads to 
hypermetabolic state, by altering the glucose and amino acid levels in the plasma. 
During this state there will be abnormal glucose production in the liver. Protein 
levels also altered in the muscle. 
 In healthy individuals, during starvation state glucose production occurs by 
using muscle protein. This process occurs slowly, so the lean body mass is 
maintained. This adaptive system is absent in malignancy that results in obvious 
reduction in protein level which leads to muscle atrophy. These metabolic 
alterations are mentioned in table 2. The results of cancer related under nutrition 
are explained in the figure 2.  
 
Loss of Weight 
 Loss of weight is defined as under-nutrition in cancer patient. More weight 
loss seen in head and neck and gastrointestinal malignancies. Approximately 54% 
of patients suffer from weight loss prior to treatment2. It suggests that cancer 
related under nutrition starts even before the development of symptoms. More than 
45% of cancer patients lose greater than 10% of their pretreatment weight during 
chemotherapy. 
 Lung cancer patients also often lose weight. The incidence varies form 45-
69% with median percentage of weight loss is 6.5%7. The frequency of weight loss 
depends on the stage of the disease and number of anatomic sites involved with 
metastasis. Weight loss is more in advanced stage than in early stage8.(Figure3) 
 Prognostic significance of weight loss before starting chemotherapy has 
been analyzed in many studies9. These studies were concluded that those patients 
who did not have loss of weight lived longer than who lost weight before starting 
treatment(Figure 4). These studies were done in patient with breast, colon, prostate 
and lung cancer. 
Cachexia 
 Cancer cachexia is a severe form of malnutrition. It is a result of prolonged 
and persistent malnutrition. It usually occurs in advanced stage. Uncorrected 
cancer related symptoms like, nausea, vomiting, pain, dyspnoea and fatigue affects 
the food intake that leads to severe weight loss. 
 Cancer cachexia is a specific form of cancer associated malnutrition, usually 
occurs in later stage. The manifestations of cancer cachexia are increased weight 
loss, reduction in lean body mass and wasting of the muscles. Persistent nausea, 
weakness, early satiety, fatigue and depression are the other features present in 
cancer cachexia10. 
 Understanding the development of cachexia is difficult. 
The two explained reasons are;11 
1. Under-nutrition due to reduced intake. 
2. Alterations in protein, fat and carbohydrate metabolism in the host. 
In cachexia, 60-70% of patients had reduced food intake12. Although 
anorexia contributes to malnutrition, cachexia is a result of tumor induced 
alteration in host metabolism13. In cancer patients, Insulin, which helps in utilizing 
Carbohydrate in muscle insulin sensitivity, is altered. Cancer is a negative energy 
balance state as a result of increased weight loss and reduced food intake.(Table2) 
More than 50-80% of cancer patients suffer from cachexia related morbidity and 
mortality14. Occurrence of cachexia depends on site of the malignancy. It is more 
common in gastrointestinal, lung and prostate cancers. It is rare in hematological 
and breast cancers. 
Cachexia patients initially have minimal weight loss that progress to severe 
muscle wasting. 
Cachexia stages are – pre-cachexia and cachexia syndrome.  
Precachexia has minimal impact on survival, but cachexia syndrome 
severely affects the quality of life and survival. The pathway of cancer cachexia is 
shown in Figure 5. 
Key features of cachexia are;5 
1. Reduced food intake (<1500 kcal/day) 
2. Loss of weight (>10%) 
3. Elevated C-reactive protein > 10mg/l 
In lung carcinoma, weight loss is a major prognostic factor. If weight loses is 
30%, it indicates that they already lost 85% of total body fat and 75% of muscle 
protein.13 This much weight loss results in weakness, reduced mobility, decreased 
organ function and finally ends in death. 
If weight lose is >15%, this results in decreased organ function associated 
with 30% mortality13. 
Mediators of Cachexia 
 Many cytokines are released during the growth of tumor in the body. These 
factors also affect the host hormonal status. Both tumor related factors and host 
hormones together changes the carbohydrate, fat and protein metabolism. These 
factors also affect the intake of food which leads to muscle atrophy15.(Table 3) 
 Host immune system produces a number of factors to combat this problem. 
Tumor necrosis factor alpha (TNFα) usually elevated. These factors contribute in 
decreased appetite, reduced food intake, increased breakdown of muscle protein 
loss of adipose tissue and loss of weight. TNF-α Promotes insulin resistance. 15,16 
 Insulin, glucagon and cortisol are affected in cancer. Cortisol or glucagon is 
increased. Cachexia causes peripheral insulin resistance. 
Cachexia patient had high levels of 13,16 
1. Proteolysis – inducing factor (PIF) 
- It induces the proteasome pathway that results in protein 
breakdown. 
2. Lipid mobilizing factor (LMF) 
- It induces lipid degradation. 
Two hallmark of cachexia are 
1. Increased apoptosis as a result of increased PIF and TNFα 
2. Excessive loss of skeletal muscle mass. 
 
Event that occur in cancer cachexia are shown in table 4. Multi factorial 
causes of cancer cachexia are explained in figure 6. 
Immune and Inflammatory markers: 
 Cancer is an inflammatory condition. Altered metabolism of cancer is a 
result of inflammatory response. In this condition many inflammatory cytokines 
are elevated. The level of these markers depends on the disease stage. 
  Commonly elevated markers are, C-Reactive protein, Tumor Necrosis 
factor- α, Interleukin-1, Interleukin 4, Interleukin- 6, IL-8 and IL-10. 
C-Reactive Protein (CRP) 
 CRP is synthesized in the liver; it is under direct transcriptional control of 
IL-6 and indirect centre of IL-1, TNF-α. CRP is usually elevated in all 
inflammatory conditions including cancer. CRP levels usually raises >10mg/l in 
cancer patients. 
  
  
 
 
 
STUDY 
 
NUTRITIONAL ASSESSMENT AND  
INTERVENTION IN LUNG CANCER PATIENTS  
UNDERGOING TREATMENT 
 
 
 
 
 
 
Nutritional, Screening, Assessment and Intervention: 
Components of nutritional care 
1. Screening 
2. Detailed nutritional assessment 
3. Nutritional therapy planning 
4. Advise to patients and their family members 
5. Reassessment 
6. Evaluation of efficacy of nutritional intervention. 
Comprehensive nutritional care in cancer is explained in figure 7. 
Nutritional Screening 
All cancer patients should be screened for nutritional status before starting 
any treatment. 
The benefits of screening are: 
1. Assessing baseline nutritional status. 
2. Helps in preventing further reduction of nutritional status. 
3. Helps to guide the selection of treatment. 
4. Helps in maintaining the quality of life. 
 
 
Screening Assessment Tools 
Simple methods of nutritional screening are; 
1. Percentage of weight loss 
2. Reduction in BMI (<20 kg/m2) 
3. Low levels of serum proteins like, 
a. Serum albumin < 2.1 g/dl 
b. Serum prealbumin < 10mg/dl 
c. Serum transferrin < 100 mg/dl 
 Many tools are available for hospitalized patients. But only 3 tools validated 
in cancer patients. (Table 5)  
While doing validation of these screening tools it should always correlated 
to the changes in the anthropometry, percentage of weight loss and serum protein 
levels. 
1. Malnutrition screening tool 
2. Mini Nutritional Assessment Tool (MNT) 
3. Scored PG SGA. 
1. The Malnutrition screening tool 17 
• It is a simple and short screening tool having 3 items. 
• It is commonly used in cancer patients on radiotherapy and acutely ill 
patients.18 
2.  The Mini Nutritional Assessment tool (MNT)19 
 It has 18 questions. The questions are useful for screening and assessment. 
The total score is 0-30 points; 
Score <17 point   – Malnutrition 
Score 17-23.5 points  – Risk of malnutrition. 
It is mainly used to assess nutrition status of elderly population; it in use in 
cancer population is limited. 
3. Score patient generated subjective global assessment (SPGSGA)20 
 This is the most validated tool to screen and assess the nutritional status in 
cancer patients. 
It had 2 components, 
First – Set of questions are completed by the patient. Second component is 
filled by health care persons. 
First component of questions are related to patient food intake, physical 
activity, weight loss history and symptom status. 
Second component of questions helps the health care person to assess the 
disease status, metabolic demand, like fever, edema and physical status of the 
patient. 
Based on subjective assessment of (SGA) patient can be grouped into;21 
SGA – A - Well nourished 
  B - Moderately nourished 
  C - Severe Malnutrition 
Based on the numerical scores patient can be managed like, 
Nutritional Triangle Recommendation22 
Score 0-1 = No dietary counseling. 
Score 2-3 = Advice is needed for patients and their family  
   members 
Score 4-8 = Dietary counseling is must 
Score >8 = Needs nutritional intervention along with    
  symptom control. 
This PG-SGA score is highly reproducible 23,24 
- It is used to monitor the response of intervention 
- It has high sensitivity and specificity 
- It correlates with objective parameters 
  
Nutritional Assessment: 
 After screening, risk groups are identified. They should under go detailed 
nutritional assessment. Nutritional assessment is done by trained dietician. 
Nutritional Assessment includes 
1. Measurement of Weight, BMI, % of weight loss, and other anthropometric 
parameters. 
2. Measurement of serum proteins like albumin. 
3. Collecting co-morbidity details of the patient. 
4. Assessing symptoms related to cancer. 
5. Assessment of daily dietary intake. 
6. Assessment of physical and functional well being. 
7. Assessment of patients and family belief. 
Anthropometric Measurements 
Varies parameters are used to assess body size and composition. 
Body size assessment parameters are; 
1. Weight 
2. Ideal body weight 
3. Adjusted body weight 
4. Usual body weight 
5. Percentage of weight loss 
6. Height 
Body compositions are assessed by; 
1. Triceps, skin filed thickness, and mid-upper arm circumference. 
2. Measurement of mid arm muscle circumference 
3. Body Mass Index (BMI) 
4. Lean Body Mass (LBM) 
5. Bioelectric Impedance Analysis (BIA) 
Measurements 
1. Weight  
- Weight should be measured during every visit. 
- Same weighing scale to be used every time. 
- Any changes in the weight indicate the health status. 
2. Usual Body Weight (UBW) 
- This is the weight patient remembers. 
3. Percentage of Weight loss 
It is calculated from the formulae. 
% Weight Loss =
Usual Weight − Present Weight
Usual Weight
 
  
Significant Weight Loss : 
Time Period Significant Loss Severe Loss 
1 Week 
1 Month 
3 Months 
6 Months 
1-2% 
5% 
7.5% 
10% 
>2% 
>5% 
>7.5% 
>10% 
 
Height: 
• Height of the patient usually measured at the first visit. 
• Height usually unaffected in Adults with malnutrition. 
• Height is measured by using height measuring device or measuring tape 
placed on the wall. 
Triceps: (Skin fold or Mid arm circumference) 
Triceps skin fold thickness – measure the subcutaneous fat. Triceps skin fold 
reflects the body fat change. 
TSF changes can be assessed every 3-4 weeks. 
Mid Arm Circumference (MAC) 
 It is measured at mid point between acromian process of scapula and 
olecrenon process of ulna by using measuring tape. 
 Mid Arm Muscle Circumference (MAMC) 
 It is calculated from mid arm circumference and triceps skin fold thickness. 
MAMC (CM) = MAC (CM) – (pi x TSF(mm)) 
Body Mass Index (BMI) 
 BMI  = Weight / Height (m) 2 
 BMI = highly correlate with body fatness 
 Normal BMI limit for Indians in 
Underweight  = <18.4 kg/m2 
Normal  = 18.5 – 22.9 kg/m2 
Overweight  = 23 – 24.9 kg/m2 
Obese  = >25 kg/m2 
Body composition  
• Body composition measurements are better marker of nutritional status of 
patient. 
• It is useful to give patient specific nutritional counseling. 25 
• It is useful to monitor the response to nutritional therapy. 
• Commonly used measurements are Lean Body Mass and Bone Mineral 
Density. 
Lean Body Mass or Lean Body Weight 
 It refers to the weight of all body organs, bone and muscles without fat. 
Formulae 
For Men : LBM = (0.32810 x Wt) + (0.33929 x Ht) – 29.533.6 
For Women : LBM = (0.29569 x Wt) + (0.41813 x Ht) – 43.293.3 
 Wt – Body weight in kilograms. 
 Ht – Body height in meters. 
Nutritional Intake Assessment 
Food intake assessment includes 
1. Details about regular diet 
2. Frequency of intake 
3. Intake of snacks 
4. Amount of food intake 
5. Changes in the dietary pattern 
6. Details of food restrictions 
7. Details of dietary supplement 
  
Patients’ symptom related assessment includes 
1. Presence of nausea or vomiting 
2. Difficulty in chewing and swallowing 
3. Taste and smell alteration 
Food intake assessment methods are 
1. Random weekly, food intake. 
2. 24 hr recall 
3. 2 week days food intake + 1 weak end food intake. 
 The 24 hours dietary recall is the gold standard method to collect the dietary 
data. 
 The advantage and disadvantage of various dietary methods are mentioned 
in table 6. 
Biochemical Markers: 
Protein status 
 To assess the nutritional status serum levels of hepatic proteins like albumin, 
transferring and pre albumin are measured. They indicate the severity of illness and 
correlate with morbidity and mortality.  Prealbumin levels indicate acute 
nutritional repletion. Serum proteins level indirectly gives the information about 
the visceral protein levels. If food intake is less, hepatic synthesis also reduced. 
 Half life of Albumin – 15to 20 days 
Half life of Transferrin  – 8 days 
Half life of Pre-albumin  – 2 to 3 days. 
1. Serum albumin 
 Commonly used prognostic marker. 
 Half life (15-20 days) 
 It is slowly respond to dietary intervention. 

 It is as baseline nutrition marker.26 
 Predicts the prognosis in colorectal cancer27 
 But it is not useful to assess the short time changes after 
nutritional intervention. 
2. Transferrin 
 It is synthesized in the liver. 
 It has short and half life (8-10 days) 
 It acts as an iron transporter. 
 It levels are affected by renal impairment, surgery. 
Since serum transferrin levels are reduced in chronic inflammatory 
conditions and its use as a marker of nutrition status are limited. 
3. Prealbumin 
It is used to assess the short-term nutritional intervention since it has 2-day 
half life.28 It is unaffected by hydration status. Its level may be reduced with 
hepatic dysfunction, acute catabolic stress, sepsis, surgery, and trauma. 
Risk of malnutrition depends on the level of prealbumin, 
Level <100 mg/l  – Severe risk  
Level 100 to 170mg/l – Moderate risk 
Level > 170 mg/l  – No risk 
Relation between C-Reactive Protein & Prealbumin 29 
 During cancer and other inflammatory conditions acute phase proteins like 
C-Reactive Protein (CRP), α1-acid glycoprotein and fibrinogen are elevated. At 
that time, pre albumin levels are reduced due to reprioritization of synthesis of 
CRP in the liver. 
Nutrition Intervention 
 Dietary interventions are, 
1. Nutritional counseling 
2. High caloric, oral protein supplements 
3. Enteral and parentral nutrition. 
In cancer patient, the type intervention is decided by the following factors. 
1. Baseline nutritional status or deficit 
2. Ability of oral intake 
3. Gastro intestinal tract integrity 
4. Performance status 
5. Treatment side effects 
6. Family background 
7. Cost of the intervention 
Estimation of Nutritional needs 
Calorie need: 
 Calorie needs depends on the histology of the cancer. Some cancers are 
considered hyper metabolic based on Basal Energy Expenditure (BEE). 
Hepatocellular carcinoma and pancreatic tumors are hyper metabolic cancer.30.31 
 Lung cancer, colorectal, esophageal and liver metastasis are not considered, 
to have hyper metabolic state based on BEE.32,33 
 Calorie expenditure is determined by calculation of basal metabolic rate by 
direct or indirect calorimetry. 
 These methods are costly and are available only in few laboratories. 
 Harris & Benedict developed simplex method to calculate the expected 
metabolic rate (Table 7). To derive the predicted total energy expenditure (TEE) 
Harris-Benedict equation is multiplied by stress factor (Table -8)34 
Determination of calorie needs in cancer patient.35 
For weight maintenance  = 1.15 x BEE kcal/d 
For repletion and anabolism = 1.5 x BEE kcal/d 
Oral supplements that provide 1 kcal/ml is not useful to improve the 
nutritional status. But supplements that gives 1.5 kcal/ml helps in maintaining 
weight.36 
Measurement of protein needs 
 Cancer is a hyper metabolic state. Measurement of urinary nitrogen loss is 
the best method to calculate protein requirements. This method is impractical and 
difficult to collect 24 hr urine and fecal samples for calculation of total nitrogen 
output. 
 The degree of protein loss and metabolic stress factors determine the amount 
of protein needed. 
 For well nourished individual  – 0.8 to 1.0g/kg IBW 
 For cancer patients   - 1.5 to 2g/kg IBW 
 IBW – Ideal Body Weight 
 Table 9 gives the details of protein requirement calculation. 
  
Routs of Nutritional Intervention 
1. Oral route 
2. Enteral nutrition 
3. Parenteral nutrition 
Oral Route 37 
• Less expensive and most preferred mode of intake. 
• Home made diet plans can be advised. 
• Many energy dense supplements are available. 
• This oral route is better tolerated by patient. 
• It improves appetite 
• It maintains gut integrity 
Enteral Nutrition38 
• It is the method of delivering nutrients into gastro intestinal tract by tubes or 
catheter. (Figure -8) 
• It is mainly indicated in patients who cannot eat sufficiently. 
Choice of external feeding determined by 
1. Clinical condition of the patient 
2. Aspiration risk 
3. Duration of feeding 
 Nasogastric Tube 
Nasoduodenal Tube   = useful for short term feed 
Nasojejunal Tube    (<3-4 Weeks) 
If risk of aspiration is present Nasoduodenal and nasojejunal tube is 
preferred. 
Long term feeding is more than 3-4 weeks then feeding tube enterostomies 
are advised. 
Methods :  
• Esophagostomy 
• Gastrostomy 
• Jejunostomy 
If risk of aspiration is present jejunostomy is the best method. 
Parentral Nutrition:39 
Indication: 
1. Reduced food intake >7 to 10 days. 
2. Loss of weight 
3. Patient who could not take food by oral or enteral route. 
  
Quality of life QOL: 
 Quality of life is important parameter analyzed in clinical studies. QOL 
depends on disease status, treatment, and its toxicity. 
 Cancer treatment reduces the tumor burden and improves the quality of life. 
 But treatment related toxicity may affect the patient quality of life. This can 
be overcome by anticipating and making necessary measure to reduce the toxicity. 
Other measures are; 
1. Changing the treatment plan 
2. Reducing the doses 
3. Providing supportive measures 
4. Changing the route of drug administration 
Now most of the cancer patients live longer even with disease, which is 
controlled by medication. They should lead normal life without or minimal toxicity 
from the treatment. So assessing quality of life is very important in ontological 
treatment. 
Commonly used QAL questionnaire in lung cancer studies are (table-11); 
1. EORTC C-30 40 
2.
 Lung Cancer Symptom Scale 41 
3. FACT-L 42 
1. EORTC – QLQ 30, QOL-LC 13 
 - It is specific for lung cancer. 
- It is used in most of the lung cancer trials. 
2. Lung Cancer Symptom Scale (LCSS) 
 - It is more specific for lung cancer. 
- It addresses specific symptoms related to lung cancer. 
3. FACT-L Functional Assessment of Cancer Therapy – Liz. 
 - It has 44 items 
 - It is available in 8 languages 
 - It is currently used in many phase 2&3 clinical studies that is        
related to lung cancer. 
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LITERATURE REVIEW OF SIMILAR STUDIES 
Guarcello et at. 43 did a study on EPA-enriched oral nutritional support in 
patients with lung cancer. He analyzed the benefit of EPA riched,  oral supplement  
in lung cancer patients. 
 The investigator enrolled 46 malnourished lung cancer patients               on   
chemotherapy . The study group (n=26) was advised to take   2 cans a day of an 
EPA-enriched oral supplement for 60 days. The control group (n=20) was advised 
to take 2 cans a day of an iso-caloric, iso-nitrogenous, oral supplement which did 
not have EP. Weight gain, appetite, energy and protein intake, quality of life, 
biochemical parameters like C-reactive protein, transferring and prealbumin levels 
are measured at the time of enrolment, at 30 days and at 60 days in both groups. At 
the end of the study he concluded that lung cancer patients who received EPA 
riched oral supplement had significant benefit in the   analyzed parameters and 
reduction of   C-reactive protein levels.  
BS van der Meij et al44 did RCT on the role of supplementation of n-3 
polyunsaturated fatty acids (PUFA) in lung carcinoma patients during treatment. 
He assessed the quality of life, performance status, handgrip strength and physical 
activity . He enrolled 40 patients totally and randomized to study and control 
groups. The study group received PUFA 2.02g EPA and 0.92g DHA per day. The 
control group received iso-caloric supplements. 
He analysed the QOL, PS and hand grip strength and physical activity of the 
pts in both group. At the end of the study, the interventional group had a 
significantly better analytical parameters after 5 weeks. No difference observed in 
hand grip strength between the groups. He concluded n-3 PUFA may beneficially 
affect QOL, PS and physical activity in lung cancer patients. 
Nicole kiss et al,7 did a systemic review on studies related to dietary 
counselling (DC), oral supplements (OS) during treatment in lung cancer patients 
up to March 2012. In this review he included 3 RCT, 1 historical control and 1 
case series. 
He examined, if DC and OS during treatment affects the nutritional status, 
functional status, QOL, and treatment outcome. He found that, DC consistently 
improves the dietary energy and protein intake during treatment. Some low level 
evidence suggested that DC or OS may reduce percentage of wt loss and maintain 
the nutritional status during treatment. Only limited evidence seen on effect on 
QOL and functional status and no evidence located for treatment outcome and 
survival in lung cancer patients. 
Another multicentric RCT done by C Baldwin et al45  with the aim  of  the 
effect of diatetic and oral energy dense supplements in relation to survival and 
QOL in patients with lung and GI malignancies receiving palliative chemotherapy. 
He enrolled a total of 358 patients, including 254 GI cancer patients and 81 lung 
cancer patients in this study and they were randomized to receive either 1. No 
intervention, 2. Nutritional supplements  (2550 Kj/day and vitamins), 3. Dietary 
advice  and 4. Diatary advice  and nutritional and vitamins supplements for 6 
weeks. He also assessed  QOL at 6 and 26 weeks by using EORTC C30. Follow up 
period was 1 year. 
The one year survival for all patients combined was 37.8% and there were 
no survival benefits in between the intervention groups. There is no significant 
difference in improvement in QOL in all groups. 
 The same investigator did a meta-analysis 46 on oral nutrition interventions 
in undernourished cancer patients.  He analyzed 13 studies which include 1414 
patients with various cancers including lung cancer. The end points which 
analyzed were nutritional and clinical outcome and QOL with oral nutritional 
interventions. 
Finally he found that the dietary counselling and oral supplements were 
resulted   in weight  gain and  increased energy intake compared with routine care 
but nutritional interventions had no benefit on survival.  
 
 
 
 
 
 
Study 
Nutritional assessment and intervention in lung cancer patients undergoing 
treatment 
Aims and Objectives 
The aim of the study is to find out if dietary counselling (DC) and  Nutritional  
intervention before, and during chemotherapy with or without radiotherapy 
treatment helps to reduce weight loss , improve quality of life and treatment 
tolerability in patients lung cancer. 
Primary Objectives 
1. Assessment of nutritional status in lung cancer patients by using parameters 
like appetite, PGSGA score,  percentage of weight loss, Lean Body Mass 
,Mid Arm Muscle Circumference and biochemical markers - C-Reactive 
Protein and Prealbumin. 
2. Analysis of outcome of nutritional intervention after 8weeks in terms of 
Energy intake, Weight gain and Quality of Life. 
Secondary Objectives 
       Assessment  of chemotherapy tolerability and toxicity. 
 
  
ARMS OF THE STUDY 
ARM 1: USUAL CARE   which consists of one-to-one dietary counselling in 
person  once  prior to starting and every cycle of chemotherapy for between 15 to 
30 minutes each.  This patients takes usual diet only. 
ARM 2: MEDICAL NUTRITION THERAPY.  This will involve indivualised  
one-to-one dietary counselling in person   once prior to starting , and every cycle of 
chemotherapy. Each session will be between 15 to 30 minutes duration depending 
on the degree of nutritional issues identified. Patients  in this group advised to take 
FDA approved nutrient dense high protein oral supplement that provides 450Kcal 
and 34 g protein per day for minimum of 8weeks.  
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METHODOLOGY  
Materials and Methods:  
Study period: From October 2012 to February 2013 
Study design : Randomized control trial 
ELIGIBILITY CRITERIA: 
Forty  nine  patients with lung cancer who satisfied the following eligibility criteria 
were included in this study. 
1. Age >18 years 
2. Gender  : Both male and Females 
3. Histologically   diagnosed of  lung cancer on chemotherapy with or without 
Radiotherapy. 
4.  Performance status  3 or less according to ECOG score 
5.  Life expectancy >2 months 
EXCLUSION CRITERIA: 
1) Lung cancer patients on supportive care only. 
2) Performance status -4 according to ECOG score. 
3) Patients with a cognitive impairment or psychiatric illness. 
 PRETREATMENT WORK UP 
1. Complete clinical examination 
2. Complete haemogram 
3. Biochemical investigations to assess renal function and liver function. 
4. Histopathological documentation 
5. Chest X-ray 
6. CT Scan Chest and abdomen 
7. Skeletal survey / Bone scan 
ASSESSMENTS OF PARAMETERS: 
          Appetite  was  assessed by visual analogue scale (0 = lack of appetite; 100 = 
hunger). (Figure 10) 
         Performance status was recorded by using  ECOG  score . (Table 12.) 
        Nutritional risk assessment was done by PGSGA score at time of initial 
presentation and every cycle of chemotherapy.  (Figure 11) 
Anthropometric indices   
1. Height (m),  - measured by measuring tape fixed on the wall. 
2. Weight (kg), - measured by digital weighing scale. 
 
 3. Percentage body weight loss  measured by 
              
             UBW – USUAL BODY WEIGHT 
4. Body Mass Index - measured by 
BMI = WEIGHT (kg) / HEIGHT (m)2 
5. Lean Body Mass   - measured by  
For men : LBM = (0.32810XWT)+(0.33929XHT) - 29.5336 
For women LBM = (0.29569XWT) +(0.41813X HT) – 43.2933 
6. WT- Body weight in kilograms, HT – Body height in meters 
7.  Triceps skin fold thickness,  
8.   Mid arm muscle circumference (calculation based on mid arm  
Circumference –MAC and Triceps skin fold thikness (TSF) 
MAMC =  MAC (cm) – ( 0.314  X  TSF(mm))  
Daily   dietary   intake  was calculated based on the 24 hour recall provided 
by the patient. This data on food intake would be translated into energy and protein 
intakes by means of specific tables validated for Indian foods by National Institute 
of Nutrition (NIN) Hyderabad. 
Quality of life was determined via Functional Assessment of Cancer 
Therapy - Lung questionnaire, (FACT-L version 4) before and every cycle of 
chemotherapy. 
Chemotherapy toxicity was assessed by Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0 
Biochemical analysis like  serum levels of CRP and prealbumin levels were 
measured before and at 8 weeks of treatment. 
BLOOD SAMPLE COLLECTION 
         Two ml of peripheral blood was collected in tubes with no anticoagulant at 
the time of starting first cycle of chemotherapy and 3rd cycle of chemotherapy ( 8 
weeks after first cycle of chemotherapy).  From this serum is extracted by 
centrifugation and stored in the  Institute of Biochemistry at – 200 C. This sample 
is used for analysis of C - reactive protein and Prealbumin. These proteins are 
quantitatively analysed by immunoturbidimetric method by using Merck Micro 
Lab 300 semi automated analyser in the Institute of Biochemistry in our hospital. 
STATISTICAL METHOD  
 We used   paired‘t’ test statistical method to compare the measured 
parameters in this study by using SPSS version 16 software. 
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STUDY ANALYSIS AND RESULTS 
  Out of the 782 cancer patients treated between October 2012 and February 
2013 in our Medical Oncology Department, 76 (9.7%) patients are presented with 
Lung cancer. PGSGA score 8 or more at time of enrolment was used to select the 
patients both in the usual care (control arm) and medical nutritional therapy (study 
or interventional arm) groups. Total of   49 Lung cancer patients who met the 
eligibility criteria entered into this study. Among them   6  patients were removed 
from the study due to early death, poor follow up and poor compliance to 
intervention. 
PATIENTS CHARACTRISTIC 
The  age ,sex and  histology distribution are matched in both groups. Patient 
base line characters are given in the table 13.   
In usual care group 22 patients (16 men, 6   women ) were included. Median 
age  of this group was 56 years  (range 32- 75years ). Twenty patients were 
diagnosed to have NSCLC and 2 patients had a diagnosis of SCLC.  
Twenty one patients (16 men, 5 women ) were randomly assigned in the 
Medical Nutritional therapy(MNT) group. Their median age was 58   years (range 
50- 66years  ). Twenty patients were diagnosed to have NSCLC and one patients 
had a diagnosis of SCLC.  
 In this  study  one non smoker developed adenocarcinoma and all others 
used to have some form of tobacco  for more than 30 years. Twelve patients had 
type 2 diabetes mellitus (usual care 6, MNT 6).  Thirteen patients   were in stage III 
(Usual care 8, MNT 5),  29 patients (usual care 14, MNT 15) are in stage IV. 
Among the stage IV   19 patients had pleural effusion, 6 patients had brain 
metastasis,  2 had liver metastasis and 1 with bone metastasis. 
One patient with stage IB had left upper lobectomy followed  by  adjuvant 
chemotherapy. Thirteen patient received concurrent chemoradiation. Eighteen 
patients received chemotherapy alone. Six patients received whole brain 
radiotherapy followed by palliative chemotherapy. 
Most commonly used chemotherapy regimen was   cisplatin and etoposide  
(usual care 20, MNT 19). The other regimen carboplatin with Paclitaxel was used 
in 4 patients. Both groups tolerated the chemotherapy. 
  We assessed treatment related toxicity by using Common toxicity criteria for 
Adverse Events version 4. Twenty patients (Usual care 11, MNT 9) experienced 
grade 3 fatigue, 7 patients experienced grade 3 cough, 9 patients had grade 3 
nausea and vomiting. Four patients received blood transfusion for grade 3 anemia. 
The toxicity were evenly distributed in both groups. 
 
 
1.  
2.  
3. AGE DISTRIBUTION (Figure 14) 
 In  this study in usual care group we enrolled patients between 32- 75 years 
of  age. The median age  was 58 years and most (63.6%) of the patients in 5th &6 th 
decade. In medical nutritional therapy group patients age ranges from 50- 66 
years.that is 100% are in 5th & 6th decade . The median age in this group was  
years. 
AGE (YEARS) USUAL CARE 
(N=22) 
MEDICAL NUTRITIONAL 
THERAPY (N=21) 
31- 40 2 0 
41-50 5 3 
51-60 7 12 
61-70 7 6 
71-80 1 0 
 
4. SMOKING PATTERN  (Figure 15) 
 Voluntary smoking is the most common cause for lung cancer development.  
In both groups voluntary smokers are more (>60%) 
SMOKING PATTERN 
 
USUAL 
CARE (N=22) 
MEDICAL NUTRITIONAL 
THERAPY (N=21) 
VOLUNTARY 14 (63.3%) 15(71.4%) 
INVOLUNTARY 4 4 
SMOKELESS TOBACOO 
USE 
4 1 
NON SMOKER 0 1 
3. TOXICITY DISTRIBUTION  
 In our study toxicity were analysed  according to CTCAE version. In both 
group patients had comparable toxicity. 
TOXICITY GRADE 3/4 USUAL CARE 
(N=22) 
MEDICAL 
NUTRITIONAL 
THERAPY (N=21) 
ANEMIA 2 2 
NAUSEA 5 4 
VOMITING 3 2 
DIARRHEA 2 4 
FATIGUE 11 9 
BRONCHIAL 
OBSTRUCTION 
3 2 
BRONCOPULMONARY 
HEMORRHAGE 
1 1 
BRONCHIAL SPASM 3 2 
COUGH 5 6 
DYSPNEA 7 6 
PLEURAL EFFUSION 10 9 
PLURITIC PAIN 3 2 
PNEMONITIS 4 2 
VOICE ALTERATION 2 2 
WHEEZING 5 4 
 
APPETITE: 
During every visit for chemotherapy patients appetite was evaluvated by 
using Visual Analog  hunger scale. After nutritional counselling  mean appetite 
value is increased in usual care group. In the same way MNT group patients oral 
protein supplementation and nutritional counselling improves the appetite. 
 PATIENT-GENERATED SUBJECTIVE GLOBAL ASSESSMENT  SCORE 
: 
We included the lung cancer patients who had base line PGSGA score of 9  
or more in this study. These patients are randomized to usual care group and MNT 
group. PGSGA score was recorded during every visit. 
In usual care group the base line mean PGSGA score  was 12.95 which 
drops to mean value of 9.86 at 8 weeks. In MNT group also the mean value of 
PGSGA score was dropped from 13.19 to 9.61. which shows not only the 
nutritional supplementation but also nutritional counselling improves the 
nutritional outcome. 
ANTROPOMEMETRIC  MEASUREMENTS: RESULTS 
The weight, triceps skinfold thickness (TSF) and midupper arm 
circumference (MUAC) were measured every visit. Height was measured at first 
visit .  
WEIGHT : 
In usual care group, the mean weight was   47.46 kg  at first visit , it increased to 
48.06 Kg at 8 weeks. In MNT group , the mean weight  was increased from 46.8 
Kg  to 48.21kg at 8 weeks.  Both nutritional  counselling and intervention 
improves the weight gain significantly (p =0.00) in lung cancer patients. 
PERCENTAGE OF WEIGHT LOSS AT THE TIME OF ENROLMENT. 
At the time of enrolment  28 patients (usual care 14, MNT 14) had  > 10% weight 
loss. 
Percentage of wt loss Usual care(N=2) MNT(N=21) 
<5% loss 0 1 
5-10% loss 8 6 
11-20% 12 10 
>20% 2 4 
 
LEAN BODY MASS  
The mean lean body mass in usual care patient at Ist visit is 39.82kg ,     at 8 
th week it is 40.15 kg. In MNT patients LBM at Ist visit is 39.54kg and at 8 th 
week  it is 40.38 kg. Both nutritional  counselling and intervention improves the 
lean body mass significantly (p =0.00). 
MID‐UPPER ARM  MUSLE CIRCUMFERENCE (MAMC)  
               Mid‐arm muscle circumference (MAMC) was calculated with the TSF 
and the MUAC measurements (MAMC (cm) = MUAC (cm) ‐ (π x TSF (cm))).  In 
ususal care group 0.11cm decrease in mean MAMC, but it is not statistically 
significant. In MNT patients there is a gain of 0.33cm in MAMC. 
CALORIE AND PROTEIN INTAKE  
 In usual care patients the energy  and protein requirement is calculated as 
per Ideal Body Weight. They advise to take 30 kCal/ kg and 1.5g/kg protein per 
day.  Deitary  plan  was made my registered dietician  working in the Institute of  
Diabetology . Each visit dietary intake was recorded by using 24 hr recall chart. 
The mean energy intake was improved from 1719 kcal/day to 1859 kcal/day at 8 
weeks.  The protein intake was improved from 33.88g/d to 36.86g/d. 
In MNT group patients in addition to the nutritional counselling, and diet 
plan  they advise to take protein rich energy dense oral supplements.  While adding 
24 grams of  these supplements in 200ml of milk provides 223 kcal and 17 gram of 
protein. They advised to take  the same amount of supplement in the milk twice a 
day. The mean energy intake was improved from 1540kcal/day to 2060 kcal/day at 
8 weeks. The  protein intake was improved from 33.88g/d to 66.09g/d. At 8 weeks. 
  
QUALITY OF LIFE ASSESSMENT 
 Functional Assessment of Cancer Therapy-Lung (FACT-L),  was used 
which includes a questionnaire based on physical, social, emotional, and functional 
wellbeing, and lung cancer symptoms . Tamil   language  version was used in this 
study.  FACT-General ,Physical well being (PWB),Functional well being    ( 
FWB) and LCS was assessed every visit. In usual care group  FACT-G, PWB  and 
FWB stastically improved from baseline. In MNT group FACT-G,  and PWB  
stastically improved from baseline, but FWB is not improved. 
BIOCHEMICAL PARAMETER ASSESSMENT 
We used C-Reactive protein as marker of inflammation, and Prealbumin as 
nutritional marker. In usual care group the baseline CRP was reduced from   
16.26mg/dl to 14.06 mg/d at 8 weeks. In MNT group   baseline CRP was reduced 
from   16.55mg/dl to 13.05 mg/d at 8 weeks. The reduction was not statistically  
significant. 
Serum Prealbumin base line value in the usual group dropped from  65.03 
mg/dl to 44.78 mg/dl. In MNT group the prealbumin base line value improve from  
49.05 mg/dl to  58.21mg/dl. The pre albumin drop in usual care and rise in MNT 
patients was not statistically significant. 
The mean difference of the above  parameters   in the uasual care group were 
compared with MNT group. There is no statistical difference in appetite, PGSGA, 
anthropometric measurements, energy, protein intake Quality of life and bio 
chemical parameters. 
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Discussion  
Lung carcinoma is the major cause of cancer death worldwide . 
Traditionally, 8% to 84% of the patients would suffer from under nutrition 
throughout the disease course. Malnutrition  leads to poor our come. Oncology 
nutrition is the new subspeciality. Nutritional intervention will improve the 
outcome.47  Lung cancer patients are   suffering from under nutrition. The 
prevalence of malnutrition in lung cancer patients at various stages of disease and 
treatment ranges from 45 to 69%, with a median weight loss of 6.5% reported 
compared to usual weight 7. 
The reasons are, most of the lung carcinoma patients are presented at 
advanced stage with high tumor burden and hypermetabolic state and high energy 
is spent for respiratory effort.  
In our hospital nearly 250 to 270 newly diagnosed lung cancer patients are 
being treated every year. Among them 40 -60% are malnourished and they lose 
their weight during treatment. Many studies addressed nutritional assessment and 
intervention in gastrointestinal malignancies and in the Head and Neck cancer. 
Only few studies are done in lung cancer patients. 
So we decided to study the nutritional assessment and intervention in lung 
cancer patients undergoing in our Medical Oncology Department. 
  We enrolled 49 patients in this study from October 2012 to February 2013. 
Among them 6 patients dropped from the analysis duo to early death, poor follow 
up and non compliance to nutritional advice and intake. 
We assessed  the nutritional status of the patients by using Patient-Generated 
Subjective Global Assessment score. The score 9 or more are randomized to usual 
care group who received dietary counseling only and Medical Nutritional Therapy 
group who received energy dense protein supplementation which provide 450 
kcal/day and 34 g/day of protein in addition to dietary counseling. The results are 
compared in table 12 and 13. 
Weight loss is most commonly observed symptom in lung cancer which 
adversely affect the outcome.  Loss of weight is one of the predictor of shorter 
overall survival lung carcinoma patients.  Lung cancer patients who had weight 
loss > 10%  showed more symptoms,  delay in chemotherapy, anaemia   poor 
responses to chemotherapy and shorter survival .48  
 In our study, at the time of enrolment, 14 patients had percentage of weight 
loss between 5-10%, 22 patients in the range of 11-20%, and 6 patients had > 20% 
weight loss. In western standard, the mean weight loss in lung cancer is 6.5%7. 
Nicole kiss et al7 and Baldwin et al46 showed that the dietary counselling improves 
the weight gain and energy intake. In our study also, after intervention (either with  
dietary counselling (DC) or oral supplementation) there is a statistically significant 
weight gain  in both the groups. Hence at the least DC is must to improve weight 
gain and outcome and to improve QOL. Weight gain and increased energy intake 
improves the Lean Body Mass and Mid Arm Muscle Circumference values. 
(P=0.00) 
  PG-SGA score can be used as an objective measure to demonstrate the 
outcome of nutrition intervention.(?). The PGSGA score is a validated nutritional 
screening and assessment tool used in our study. Here, the PGSGA score in usual 
care group was 12.95 (ranges from 9 to 19) which was found to be reduced to 
9.86(ranges from 7 to 14) and in the MNT group, the initial score was 13.19 
(ranges from 9 to 210 and it was reduced to 9.61 (ranges from 7 to 13) at 8 weeks. 
The reduction was found to be significant in both groups (p=0.00). 
The energy intake is reduced in cancer patients because of  alteration in taste 
sensation, loss of appetite, early satiety and toxicity to the treatment. And also 
energy insufficiency occurs because of increased metabolic activity and resting 
energy expenditure. Nicole kiss et al 7 and Baldwin et al 46showed that the dietary 
counselling improves the energy intake. In our study, the mean energy intake is 
improved from 1719 Kcal/day to 1859 Kcal/day (p=0.00) in usual care group and 
in MNT group it increased from 1540Kcal/day to 2060Kcal/day (p=0.00). In the 
same way the mean protein intake is increased from 33.88g/day to 36.86 g/day in 
usual care group (p=0.00). In MNT group it is increased from 33.88g/day to 
66.09g/day (p=0.00). 
In our study we used FACT-L QOL questionnaire to assess the quality of 
life. The FACT-G is the total score of physical, functional and social well being. In 
our study we have analyzed all above said parameters FACT-G score and Physical 
well-being score are statistically improved at the end of 8 weeks of 
intervention(p=,0.05) in both the groups. The functional well being was improved 
in control group (p=0.007) but not improved in study group (p=0.729). Most of the 
studies were done using EORTC C30 tool and there is no study available to 
compare the results in lung cancer patients enrolled in nutritional studies. 
Prealbumin, is a serum protein   used  to assess the nutritional status. It is 
more sensitive to changes in protein-energy status than albumin. Its concentration 
closely reflects recent dietary intake rather than overall nutritional status. (/). 
 In our study, for the usual care group, at the time of enrolment the mean 
pre-albumin value was 65.03 mg/dl (range from 15.1 to 99.3 mg/dl) which 
decreased to 44.78 mg/dl (range from 9.2 to 231.7 mg/dl) at 8 weeks and the 
difference is not significant(p=0.804). In MNT group, initially the mean pre-
albumin value was 49.05mg/dl (ranges from 14.3 to 220.3 mg/dl). The value 
increased to 58.21mg/dl (ranges from 21.6 to 234.7 mg/dl) at 8 weeks and this 
increase  is not statistically significant (p=0.67). 
Chronic inflammatory disease, such as cancer, can produce a persistent 
increase in the serum concentration of CRP. Weight loss is the nutritional indicator 
most related to serum CRP 49. Studying patients with esophagus and stomach 
cancer, Deans et al 50, found the following variables to be determinant of weight 
loss: dietary intake, high serum CRP concentration and stage of the disease. The 
attenuation of systemic inflammatory response has been studied as a way to 
improve nutritional status. Supplementation with omega-3 fatty acids may help 
stabilize weight in cancer patients with oral dietary intake who exhibit intentional, 
progressive weight loss. Initially in usual care group, the mean CRP value was 
16.26 mg/dl (ranges from 9.73 to 26.52 mg/dl) which is reduced to 14.06 mg/dl 
(ranges from 18.60 to 22.41 mg/dl) in 8 weeks (p=0.267). In MNT group, initial 
Mean CRP value was 16.55 mg/dl (ranges from 11.26 to 26.36 mg/dl) which is 
reduced to 13.04mg/dl (ranges from 7.91 to 21.46 mg/dl) at 8 weeks which is 
highly significant (p=0.006). 
In our study we used FACT-L QOL questionnaire to assess the quality of 
life. The FACT-G is the total score of physical, functional and social well being. In 
our study we have analyzed all above said parameters FACT-G score and Physical 
well-being score are statistically improved at the end of 8 weeks of 
intervention(p=,0.05) in both the groups. The functional well being was improved 
in control group (p=0.007) but not improved in study group (p=0.729). Most of the 
studies were done using EORTC C30 tool and there is no study available to 
compare the results in lung cancer patients enrolled in nutritional studies. 
Even though there is significant differences in the mean values between the 
initial period and at 8 weeks of intervention among the group itself but there is no 
statistically significant differences noted between the usual group and the Medical 
Nutrition Therapy group in all analyzed parameters. 
Baldwin et al 45 finally stated in his study that the use of only energy dense 
high protein supplements and/or dietary advice have not shown any improvement 
in the outcome.  In our study also shows that there is added benefits of using oral 
protein supplements along with dietary counselling. 
M. Guarcello et al,43 done a study with EPA enriched oral nutritional 
supplement seems to be effective in improving nutritional status and quality of life 
in compare with iso-caloric and iso-nitrogenous non EPA enriched oral 
supplements alone. In this study he showed that there is a significant increase in 
body weight, energy and protein intake, QOL, appetite, pre-albumin and 
transferring as well as there is significant reduction in C-reactive protein levels. 
EPA reduces the inflammatory cytokine production and there by reduces the 
wasting in cancer patients. 
BS van der Meij et al 44 used n-3 PUFA along with protein supplements 
have shown the improvement in QOL, physical activity and performance status. 
The PUFA from the fish oil has an immune modulating effect by forming the 
mediators with a lower pro-inflammatory and immunosuppressive effects. 
In our study both group of patients tolerated the chemotherapy well and completed 
the course without any delay.  The toxicity were evenly distributed and tolerated 
well in both groups. 
 In summary, in our study, the dietary counselling alone or dietary 
counselling with oral supplements definitely gives a benefit in improving appetite, 
weight gain, energy intake, and QOL separately. But while comparing both the 
groups, there is no additional benefit in adding oral supplements with dietary 
counselling. These results are comparable with the studies done with dietary 
counselling with or without high energy oral supplements. Both group of patients 
tolerated the chemotherapy and its toxicity well and completed the course without 
any delay. Some studies have shown the true benefits of using oral supplements 
containing immune modulating nutritional substances like   n-3PUFA and EPA 
with promising effects. 
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CONCLUSION 
 In our study, about 65% of the enrolled patients had more than 10% weight 
loss at presentation which is a worst scenario. 
 Dietary counselling alone or dietary counselling with oral supplements 
definitely gives a benefit in improving appetite, weight gain, energy intake, and 
QOL separately. 
 Both group of patients tolerated the chemotherapy and its toxicity well and 
completed the course without any delay. 
 In conclusion, all patients with lung cancer definitely need dietary 
counselling at least to improve the weight gain and treatment tolerability. 
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Table 1: Prevalence of malnutrition for different type of cancer   (von 
Meyenfeldt, 2005) 
 
 
Figure 1: Prevalence of cancer-related symptoms and side-effects (Benjamin 
HL et al.2008) 
 
 Table 2 : Metabolic alterations in cancer cachexia 
 
Figure 2: Consequences of cancer-associated malnutrition (Caro MM et al., 2006) 
 
  
Figure 3: Percent of patients experiencing weight loss (>10%) based on stage 
of cancer (Ravasco et al. 2004) 
 
Figure 4: Effect of weight loss on survival (DeWys et al. 1980) 
 
  
 
Figure 5: The cachexia journey (Benjamin HL et al. 2008) 
 
Table 3 : Mediators of cancer cachexia 
 
 
 
 
Table 4: Factors contributing to cachexia in patients with solid tumor cancer 
 
Figure 6: Multifactorial causes of cancer cachexia (Van Cutsem E, Arends J, 
2005) 
 
 Figure: 7 Integrated nutrition care process in the continuum of cancer 
 
 
 
 
 Table 5 Screening tools validated in cancer patients 
SL.NO TOOL ITEMS DATA 
INCLUDED 
completed 
by 
REF 
NO 
1. Malnutrition 
Screening 
Tool 
3 Weight history,  
effect of appetite, 
 Patient. 16 
2. Mini 
Nutritional 
Assessment 
18 Weight history, 
food intake 
,activity, 
psychological 
stress, 
Anthropometric 
measurements 
 
Practitioner 
18 
3. Patient 
Generated 
Subjective 
Global 
Assessment 
17 Weight history, 
food intake , 
activity,symptoms, 
metabolic demand, 
physical assessment 
Patient and 
Practitioner 
20 
 
 
 
 
 
 
  
Table 6  Strengths and Limitations of Various Dietary Assessment Methods 
Used in Clinical Settings 
 
 
 
Table  7 Calculating energy requirements 
 
Table  8  Activity and stress factors for calculating total energy expenditure 
 
Table 9.  Calculating protein requirements 
 
 
 
Fig 8. Insertion and feeding points for nasogastric feeding tubes 
 
 
 
 
 
 
 
Table 10. General  guidelines/criteria for selection of route of feeding.
 
 
  Fig. 9  Impact of quality of  life  
 
 
Table 11. Characteristics of the EORTC QLQ-C30 and FACT-G compared 
 
  
STATISTIC OF USUAL CARE GROUP 
1.  WEIGHT [WT] 
 
2.  LEAN BODY MASS[LBW] 
 
3.  MID ARM MUSCLE CIRCUMFERENCE[MAMC]
 
4.  APPETITE 
 
5.   PATIENT GENERATED SUBJECTIVE GLOBAL 
 ASSESSMENT[PGSGA] 
 
6.  ENERGY INTAKE [E] 
 
7.  PROTEIN INTAKE 
 
8. QOL – FACTG 
 
 9.  PHYSICAL WELL BEING[PWB] 
 
 10.  FUNCTIONAL WELL BEING[FWB] 
 
 11.  C-REACTIVE PROTEIN[CRP] 
 
12.  PREALBUMIN[PAB] 
 
 STATISTIC OF MEDICAL NUTRIONAL THERAPY GROUP 
1. WEIGHT [WT]
 
2. LEAN BODY MASS[LBW] 
 
3.MID ARM MUSCLE CIRCUMFERENCE[MAMC] 
 
 4.APPETITE 
 
5. PATIENT GENERATED SUBJECTIVE GLOBAL 
 ASSESSMENT[PGSGA] 
 
6.  ENERGY INTAKE[E] 
 
 7. PROTEIN INTAKE
 
8. QOL – FACTG 
 
9. PHYSICAL WELL BEING[PWB] 
  
10.  FUNCTIONAL WELL BEING[FWB] 
 
11. C-REACTIVE PROTEIN[CRP] 
 12. 
12.PREALBUMIN[PAB] 
 
COMPARISON OF USUAL CARE AND MEDICAL NUTRITIONAL 
THERAPY GROUPS 
1. WEIGHT [WT] 
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5. PATIENT GENERATED SUBJECTIVE GLOBAL 
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7.  PROTEIN INTAKE 
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10.  FUNCTIONAL WELL BEING[FWB]
 
11. C-REACTIVE PROTEIN[CRP] 
 
12. PREALBUMIN[PAB] 
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PROFORMA 
NUTRITIONAL ASSESSMENT AND INTERVENTION IN LUNG 
CANCER PATIENTS UNDERGOING TREATMENT 
NAME:                                               AGE:        SEX:        MO.NO:           
STUDY NO: 
 ADDRESS &CONTACT NO: 
 
HT:             WT:             BMI:               LBM:              %OF WT LOSS: 
 
 MAC:        TST:            MAMC: 
 
APPETITE (VAS): 
ECOG PS: 
SCORED PG- SGA: 
SITE OF PRIMARY TUMOR: 
 HISTOLOGY & STAGE: 
TREATMENT DETAILS: 
COMORBIDITY: 
DATE OF ENROLLMENT: 
 
DATE OF REASSESSMENT: 1.                        2. 
 
DATE OF BLOOD SAMPLE COLLECTION:  1.                  2. 
  
 
 
  
 
Chemotherapy toxicity assessment by Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.0 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
  
 
FACIT Administration and Scoring Guidelines 
 
 
Administration: 
 
The FACIT scales are designed for patient self-administration, but can also be administered by interview 
format.  For self-administration, patients should be instructed to read the brief directions at the top of the page. 
After the patient's correct understanding has been confirmed, he/she should be encouraged to complete every 
item in order without skipping any.  Some patients may feel that a given question is not applicable to them and 
will therefore skip the item altogether.  Patients should be encouraged to circle the response that is most 
applicable. If, for example, a patient is not currently receiving any treatment, the patient should circle “not at 
all” to the question “I am bothered by side effects of treatment.”  
 
During interview administration, it is helpful to have the patient hold a card on which the response options 
have been printed. Interview administration is considered appropriate given adequate training of interviewers 
so as to elicit non-biased patient responses.  One of the aims of a large multi-center study of cancer and HIV 
patients (N=1227) was to test the psychometric properties and statistical equivalence of the English and 
Spanish language versions of the FACT subscales across literacy level (low vs. high) and mode of 
administration (self vs. interview).  Technical equivalence across mode of administration was demonstrated in 
the high literacy patients; there were no differences in data quality or in mean QOL scores, after adjustment for 
performance status rating, socioeconomic status, gender and age. Technical equivalence between modes of 
administration with the FACT permits unbiased assessment of the impact of chronic illnesses and their 
treatments on patients from diverse backgrounds. 
 
 
Scoring the FACT-G: 
 
The FACT-G scoring guide identifies those items that must be reversed before being added to obtain subscale 
totals.  Negatively stated items are reversed by subtracting the response from “4”.  After reversing proper items, 
all subscale items are summed to a total, which is the subscale score.  For all FACIT scales and symptom 
indices, the higher the score the better the QOL. 
 
Handling missing items.  If there are missing items, subscale scores can be prorated.  This is done by 
multiplying the sum of the subscale by the number of items in the subscale, then dividing by the number of 
items actually answered.  This can be done on the scoring guide or by using the formula below: 
 
Prorated subscale score = [Sum of item scores] x [N of items in subscale]÷ [N of items answered] 
     
When there are missing data, prorating by subscale in this way is acceptable as long as more than 50% of the 
items were answered (e.g., a minimum of 4 of 7 items, 4 of 6 items, etc).  The total score is then calculated as 
the sum of the un-weighted subscale scores.  The FACT scale is considered to be an acceptable indicator of 
patient quality of life as long as overall item response rate is greater than 80% (e.g., at least 22 of 27 FACT-
G items completed).  This is not to be confused with individual subscale item response rate, which allows a 
subscale score to be prorated for missing items if greater than 50% of items are answered. In addition, a total 
score should only be calculated if ALL of the component subscales have valid scores.   
 
 
NOTE: Computer programs written in SPSS and SAS for the FACIT scales and symptom indices are provided 
on diskette in Section 4 of the manual or can be downloaded from the website at www.facit.org for a nominal 
fee.  Standard raw score scoring templates for all FACIT scales and symptom indices are also provided in 
Section 4 of the manual or under the “Validity and Interpretation” section of the website. 
 
 
Scoring the Specific Scales & Symptom Indices: 
 
For the "Additional Concerns" subscale (e.g., cancer-specific questions) and the symptom indices, the 
procedure for scoring is the same as described above for the FACT-G. Again, over 50% of the items (e.g., 5 of 
9 items, 7 of 12 items) must be completed in order to consider each subscale score valid.   
 
NOTE: scoring algorithms for the FACIT-TS-G and FACIT-TS-PS are different from other FACIT scales. 
Please refer to the specific scoring templates for more detail. 
 
 
Deriving a Total Score:  
 
The total score for the specific FACIT scales is the sum of the FACT-G (the first 4 subscales common to 
almost all scales) plus the "Additional Concerns" subscale. The symptom indices do not include the FACT-G 
in the total score. By following this scoring guide and transcribing the FACT-G score, the two totals can be 
summed to derive the TOTAL FACT/FACIT SCORE.  
 
Notes:  
 
1.  Multilingual versions can be scored on the English language scoring guides. 
 
2.   Several scales have more items listed in the “Additional Concerns” subscale than are currently 
recommended for scoring.  This is usually because additional work on a given subscale has suggested a 
need for additional items.  However, it may take awhile for the new items to be validated so we don’t 
formally recommend they be included in the scoring until we know more about how the item(s) 
function.  We include the items on the scale to encourage investigators who have the time or resources 
to evaluate their data according to the existing scoring recommendations and to test out the value of the 
new item(s).  As always, we welcome collaborators to share any relevant data of this nature to help 
further reliability and validity testing of the FACIT questionnaires.  
 
 
Selecting Scores for Analyses: 
 
These scoring templates allow one to obtain two different total scores in addition to each individual subscale score. 
The FACT-G total score provides a useful summary of overall quality of life across a diverse group of patients. 
The disease-specific questionnaire total scores (i.e., FACT-G plus disease-specific subscale score) may further 
refine the FACT-G summary score.  Two alternative approaches are noteworthy, however.  One is to separately 
analyze the FACT-G total score and the specific subscale score.  Another is to select subscales of the FACT which 
are most likely to be changed by an intervention being tested.  For example, the Physical, Functional, and Cancer-
specific subscales would be most likely to change in a chemotherapy clinical trial. One could also consider 
creating a separate a priori index which sums two or three subscales.  This has been done with the FACT-L and 
many other FACIT scales, combining the Physical, Functional and 7-item Lung Cancer Subscales into a 21-item 
Trial Outcome Index (Cella, Bonomi, Lloyd et al, 1994; Brady, Cella, Mo, 1997; Cella, 1997).  On the other 
hand, the Emotional or Social Well-being subscale would be expected to change most when evaluating a 
psychosocial intervention.  
 
Comparing Version 4 scores to Previously Published (Version 2 & 3) Scores: 
 
Most of the questions from Version 3 remain intact in Version 4 (see item history table in section 3 of the manual 
for details), although some items have been reworded and a few have changed from being negatively stated to 
positively stated items.  Comparison between scale scores in these two versions is fairly straightforward. 
Adjustments must be made, however, when comparing the total FACT/FACIT score and when comparing the 
Emotional Well-Being (EWB) subscale score between the two versions. To compare Version 3 and 4 EWB scales, 
item GE6 (#25 in Version 3) must be omitted from the scoring of version 4. This can be done by scoring the first 5 
items of the EWB subscale, multiplying by 5 (not 6), and dividing by the number of questions answered (not 
including the sixth question). The Version 4 total FACT-G score has been affected by the dropping of the 
Relationship with Doctor subscale and the addition in the scoring of item GE6 (#25 in Version 3). One way to 
compare total scores is to drop item GE6 from the Version 4 scoring and add 6.85 (mean score of the RWD 
subscale as reported in Cella et al., 1993) to the sum of the four subscales (Physical Well-Being, Social/Family 
Well-Being, Emotional Well-Being, and Functional Well-Being). This will give you the best estimate for 
comparison of published FACT/FACIT data. 
FACT-L scoring template 05.21.03 
FACT-L Scoring Guidelines (Version 4) – Page 1 
 
Instructions:* 1. Record answers in "item response" column. If missing, mark with an X 
    2. Perform reversals as indicated, and sum individual items to obtain a score. 
3. Multiply the sum of the item scores by the number of items in the subscale, then divide by the   
    number of items answered.  This produces the subscale score. 
4. Add subscale scores to derive total scores (TOI, FACT-G & FACT-L).  
5. The higher the score, the better the QOL. 
 
 
Subscale    Item Code    Reverse item?       Item response         Item Score  
 
PHYSICAL GP1 4 - ________  =________ 
WELL-BEING GP2 4 - ________  =________ 
   (PWB) GP3 4 - ________  =________ 
       GP4 4 - ________  =________ 
       GP5 4 - ________  =________ 
       GP6 4 - ________  =________ 
       GP7 4 - ________  =________ 
 
              Sum individual item scores: ________   
                         Multiply by 7: ________ 
             Divide by number of items answered: ________=PWB subscale score 
 
SOCIAL/FAMILY GS1 0 + ________  =________ 
WELL-BEING GS2 0 + ________  =________ 
    (SWB) GS3 0 + ________  =________ 
       GS4 0 + ________  =________ 
       GS5 0 + ________  =________ 
    GS6 0 + ________  =________ 
       GS7 0 + ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 7: ________ 
            Divide by number of items answered: ________=SWB subscale score 
 
EMOTIONAL GE1 4 - ________  =________ 
WELL-BEING GE2 0 + ________  =________ 
    (EWB) GE3 4 - ________  =________ 
       GE4 4 - ________  =________ 
      GE5 4 - ________  =________    
 GE6 4 - ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 6: ________ 
            Divide by number of items answered: ________=EWB subscale score 
 
FUNCTIONAL   GF1 0 + ________  =________ 
WELL-BEING  GF2 0 + ________  =________ 
     (FWB) GF3 0 + ________  =________ 
       GF4 0 + ________  =________ 
       GF5 0 + ________  =________ 
       GF6 0 + ________  =________ 
       GF7 0 + ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 7: ________ 
            Divide by number of items answered: ________=FWB subscale score 
 
 
 
Score range: 0-28 
Score range: 0-28 
Score range: 0-24 
Score range: 0-28 
FACT-L scoring template 05.21.03 
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Subscale          Item Code       Reverse item?            Item response          Item Score  
 
LUNG   B1  4 - ________  =________     
CANCER  C2  4 - ________  =________   
SUBSCALE  L1  0 + ________  =________   
   (LCS)   L2  4 - ________  =________   
B5  SCORING THIS ITEM NOT RECOMMENDED  
C6  0 + ________  =________   
L3  4 - ________  =________   
L4  0 + ________  =________   
L5  SCORING THIS ITEM NOT RECOMMENDED 
 
              Sum individual item scores:________   
                        Multiply by 7: ________ 
            Divide by number of items answered: ________=LC Subscale score 
 
 
To derive a FACT-L Trial Outcome Index (TOI): 
 
 
  __________ + __________ + __________ =________=FACT-L TOI 
  (PWB score)   (FWB score)   (LCS score)   
 
 
To Derive a FACT-G total score: 
 
 
        __________ + __________ + __________ + __________=________=FACT-G Total score 
        (PWB score)    (SWB score)   (EWB score)  (FWB score) 
 
 
 
To Derive a FACT-L total score: 
 
 
              _________ + __________ + __________ + __________ + __________ =________=FACT-L Total score 
                            (PWB score)  (SWB score)   (EWB score)  (FWB score)   (LCS score) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*For guidelines on handling missing data and scoring options, please refer to the Administration and Scoring Guidelines 
in the manual or on-line at www.facit.org. 
 
 
Score range: 0-84 
Score range: 0-108 
Score range: 0-136 
Score range: 0-28 
(7-item LCS) 
 FACT-L (Version 4) 
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¸£ú¸ñ¼¨Å ¯í¸û §¿¡¨Âì ¦¸¡ñ¼ ÁüÈÅ÷¸û Óì¸¢ÂÁ¡É¨Å ±ýÚ ¦¾Ã¢Å¢ò¾ º¢Ä 
¸ÕòÐì¸û. ¸¼ó¾ 7 ¾¢Éí¸¨Ç ¦À¡Õò¾Å¨Ã, ¯í¸ÙìÌ ¦À¡Õò¾Á¡¸ þÕìÌõ À¾¢Ä¢¨É 
ÌÈ¢ì¸ ¾Â×¦ºöÐ ÅÃ¢ìÌ ´Õ ±ñ¨½ Åð¼Á¢¼×õ «øÄÐ ÌÈ¢Â¢¼×õ.   
 
 ¯¼ø ¿Äõ þøÄ§Å 
þø¨Ä 
 
º¢È¢¾Ç× 
 
µÃÇ× 
 
¸½¢ºÁ¡¸ 
 
Á¢¸ 
«¾¢¸õ 
  
 
GP1 ±ÉìÌ ¦¾õÒ þø¨Ä .................................................0 1 2 3 4 
 
GP2 ±ÉìÌ ÌÁð¼ø þÕì¸¢ÈÐ ................................ 0 1 2 3 4 
 
GP3 ±ý ¯¼ø ¿¢¨Ä ¸¡Ã½ò¾¡ø ±ý 
ÌÎõÀò §¾¨Å¸¨Ç ¸ÅÉ¢ôÀÐ ±ÉìÌ 
À¢Ãîº¨ÉÂ¡¸ þÕì¸¢ÈÐ.............................................0 1 2 3 4 
 
GP4 ±ÉìÌ ÅÄ¢ þÕì¸¢ÈÐ ................................................0 1 2 3 4 
 
GP5 º¢¸¢î¨ºÂ¢ý Àì¸ Å¢¨Ç×¸Ç¡ø ¿¡ý 
«ÅŠ¨¾ôÀÎ¸¢§Èý ...................................................0 1 2 3 4 
 
GP6 ±ý ¯¼ø ¿¢¨Ä ºÃ¢Â¢ø¨Ä ................................ 0 1 2 3 4 
 
GP7 ¿¡ý ÀÎì¨¸Â¢ø §¿Ãò¨¾ ¦ºÄÅ¢¼ 
§ÅñÊÂ ¸ð¼¡Âò¾¢üÌò ¾ûÇôÀðÎ 
þÕì¸¢§Èý ................................................................0 1 2 3 4 
 
 ºã¸/ÌÎõÀ ¿Äõ 
 
þøÄ§Å 
þø¨Ä 
 
º¢È¢¾Ç× 
 
µÃÇ× 
 
¸½¢ºÁ¡¸ 
 
Á¢¸ 
«¾¢¸õ 
  
 
GS1 ¿¡ý ±ý ¿ñÀ÷¸Ù¼ý ¦¿Õì¸Á¡¸ 
þÕôÀ¾¡¸ ¯½÷¸¢§Èý .............................................0 1 2 3 4 
 
GS2 ±ý ÌÎõÀò¾¢¼Á¢ÕóÐ ±ÉìÌ 
¯½÷×â÷ÅÁ¡É ¬¾Ã× ¸¢¨¼ì¸¢ÈÐ .....................0 1 2 3 4 
 
GS3 ±ý ¿ñÀ÷¸Ç¢ý ¬¾Ã× ±ÉìÌì 
¸¢¨¼ì¸¢ÈÐ................................................................0 1 2 3 4 
 
GS4 ±ý ÌÎõÀõ ±ý ¯¼ø¿Äì Ì¨È¨Â 
²üÚì ¦¸¡ñÊÕì¸¢ÈÐ...............................................0 1 2 3 4 
 
GS5 ±ýÛ¨¼Â ¯¼ø¿Äì Ì¨È¨Âô ÀüÈ¢ 
±ý ÌÎõÀò¾¢É÷ ¾ÁìÌû ¾¸Åø 
ÀÃ¢Á¡È¢ì¦¸¡ûÙÅÐ ±ÉìÌ ¾¢Õô¾¢ 
«Ç¢ì¸¢ÈÐ ................................................................0 1 2 3 4 
 
GS6 ¿¡ý ±ý Üð¼¡Ç¢§Â¡Î (±ÉÐ Óì¸¢Â 
¬¾ÃÅ¡Ç÷) ¦¿Õì¸Á¡¸ ¯½÷¸¢§Èý.....................0 1 2 3 4 
 
Q1 
 
¾ü§À¡Ð ¯¼ÖÈ× Å¢„Âí¸Ç¢ø ¿£í¸û ±ôÀÊ 
þÕó¾¡Öõ, À¢ýÅÕõ §¸ûÅ¢¸ÙìÌ ¾Â×¦ºöÐ À¾¢ø 
«Ç¢ì¸×õ. À¾¢ø «Ç¢ì¸ ¿£í¸û Å¢ÕõÀÅ¢ø¨Ä¦ÂýÈ¡ø 
¾Â×¦ºöÐ þó¾ ¦ÀðÊÂ¢ø  X ¦ÀÕì¸ø ÌÈ¢Â¢ðÎ 
«Îò¾ ÀÌ¾¢ìÌî ¦ºøÄ×õ. 
 
 
GS7 ±ýÛ¨¼Â À¡Ä¢Âø Å¡úì¨¸ ±ÉìÌ 
¾¢Õô¾¢Â¡¸ ¯ûÇÐ  ...................................................0 1 2 3 4 
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 ¯½÷× ¿Äõ þøÄ§Å 
þø¨Ä 
 
º¢È¢¾Ç× 
 
µÃÇ× 
 
¸½¢ºÁ¡¸ 
 
Á¢¸ 
«¾¢¸õ 
 
  
GE1 ¿¡ý §º¡¸Á¡¸ þÕì¸¢§Èý ................................ 0 1 2 3 4 
 
GE2 ±ý ¯¼ø ¿Äì Ì¨È¨Â ¿¡ý ºÁ¡Ç¢ìÌõ 
Å¢¾õ ±ÉìÌ ¾¢Õô¾¢Â¡¸ ¯ûÇÐ................... 0 1 2 3 4 
 
GE3 ±ýÛ¨¼Â §¿¡öìÌ ±¾¢Ã¡É 
§À¡Ã¡ð¼ò¾¢ø ¿¡ý ¿õÀ¢ì¨¸ þÆóÐ 
ÅÕ¸¢§Èý ................................................................0 1 2 3 4 
 
GE4 ±ÉìÌ À¼À¼ôÀ¡¸ þÕì¸¢ÈÐ ................................0 1 2 3 4 
 
GE5 º¡Å¨¾ô ÀüÈ¢ ¿¡ý ¸Å¨ÄôÀÎ¸¢§Èý ....................0 1 2 3 4 
 
GE6 ±ý ¿¢¨Ä §ÁÖõ §Á¡ºÁ¨¼Ôõ ±ýÚ 
¿¡ý ¸Å¨ÄôÀÎ¸¢§Èý ...............................................0 1 2 3 4 
 
 
 ¦ºÂøÀ¡ðÎ ¿Äõ þøÄ§Å 
þø¨Ä 
 
º¢È¢¾Ç× 
 
µÃÇ× 
 
¸½¢ºÁ¡¸ 
 
Á¢¸ 
«¾¢¸õ 
  
 
GF1 ±ýÉ¡ø §Å¨Ä ¦ºöÂ ÓÊ¸¢ÈÐ (Å£ðÊø 
¦ºöÔõ §Å¨Ä ¯ðÀ¼) ..............................................0 1 2 3 4 
 
GF2 ±ý §Å¨Ä (Å£ðÎ §Å¨Ä ¯ðÀ¼) ÁÉ 
¿¢¨È¨Å «Ç¢ì¸¢ÈÐ ....................................................0 1 2 3 4 
 
GF3 ±ýÉ¡ø Å¡úì¨¸¨Â «ÛÀÅ¢ì¸ 
ÓÊ¸¢ÈÐ ................................................................ 0 1 2 3 4 
 
GF4 ±ý ¯¼ø ¿Äì Ì¨È¨Â ¿¡ý ²üÚì 
¦¸¡ñÊÕì¸¢§Èý ........................................................0 1 2 3 4 
 
GF5 ¿¡ý ¿ýÈ¡¸ ¯ÈíÌ¸¢§Èý ................................ 0 1 2 3 4 
 
GF6 ÅÆì¸Á¡¸ Å¢¨ÇÂ¡ðÊü¸¡¸ ¿¡ý ¦ºöÔõ 
¦ºÂø¸Ç¢ø Á¸¢úîº¢Â¨¼¸¢§Èý ................................0 1 2 3 4 
 
GF7 ±ýÛ¨¼Â ¾ü§À¡¨¾Â Å¡úì¨¸ò ¾Ãõ 
±ÉìÌ ÁÉ¿¢¨È¨Å «Ç¢ì¸¢ÈÐ ................................0 1 2 3 4 
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¸¼ó¾ 7 ¾¢Éí¸¨Ç ¦À¡Õò¾Å¨Ã, ¯í¸ÙìÌ ¦À¡Õò¾Á¡¸ þÕìÌõ À¾¢Ä¢¨É ÌÈ¢ì¸ 
¾Â×¦ºöÐ ÅÃ¢ìÌ ´Õ ±ñ¨½ Åð¼Á¢¼×õ «øÄÐ ÌÈ¢Â¢¼×õ. 
 
 «ñ½ñ¢ ê¤ô ð¤óê¢ê¬ùè÷¢¢ ¢ ¢¢ ¢ ¢¢ ¢ ¢ þøÄ§Å þø¨Ä 
 
º¢È¢¾Ç× 
 
µÃÇ× 
 
¸½¢ºÁ¡¸ 
 
Á¢¸ 
«¾¢¸õ 
 
 
 
 
 
B1 âùè¢° Íê¢²î¢ î¤íøô¢ Þ¼ï¢¶ õ¼è¤ø¶ ......................0 1 2 3 4 
 
C2 âù¢ â¬ì °¬øï¢¶ õ¼è¤ø¶ ................................ 0 1 2 3 4 
 
L1 âù¢ ê¤ï¢î¬ù ªî÷¤õ£è à÷¢÷¶ ................................0 1 2 3 4 
 
L2 âùè¢° Þ¼ñô¢ Þ¼ï¢¶ ªè£í¢«ì Þ¼è¢è¤ø¶ ................0 1 2 3 4 
 
B5 º® àî¤ó¢õ¶ âùè¢°è¢ èû¢ìñ£è Þ¼è¢è¤ø¶ ..................0 1 2 3 4 
 
C6 âùè¢° ïù¢ø£èð¢ ðê¤ â´è¢è¤ø¶ ................................0 1 2 3 4 
 
L3 âù¢Â¬ìò ªïë¢² ÞÁè¢èñ£è Þ¼ð¢ðî£è  
àíó¢è¤«øù¢  ................................................................0 1 2 3 4 
 
L4 ²õ£ê¤ð¢ð¶ âùè¢° ²ôðñ£è Þ¼è¢è¤ø¶ .........................0 1 2 3 4 
 
Q3 ï¦é¢è÷¢ âð¢«ð£î£õ¶ ¹¬è ð¤®î¢î¤¼è¢è¤ø¦ó¢è÷£? 
Þô¢¬ô ___  Ýñ¢ ___ Ýñ¢ âù¤ô¢:   
 
L5  ¹¬è ð¤®î¢î¶ ðø¢ø¤ ï£ù¢ õ¼ï¢¶è¤«øù¢ .........................0 1 2 3 4 
 
